Patents by Inventor Min Michael He

Min Michael He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ORAL FORMULATION FOR DEXLANSOPRAZOLE
    Publication number: 20130273171
    Abstract: A stable formulation of dexlansoprazole for treating a digestive disorder, and methods of manufacturing the same.
    Type: Application
    Filed: November 18, 2010
    Publication date: October 17, 2013
    Applicant: HANDA PHARMACEUTICALS, LLC
    Inventors: Zhiqun Shen, Yu Zhang, Enjun Fu, MIn Michael He, Fang-yu Liu
  • Methods for making pharmaceutical dosage forms containing active cushioning components
    Patent number: 8110223
    Abstract: Novel methods for making dosages form comprising a cushioning component. The methods of the present invention provides dosage forms which can be compressed to form compressed dosage forms that are substantially uniform in composition and robust and exhibit reduced friability. The invention also relates to methods for making fast-disintegrating dosage forms.
    Type: Grant
    Filed: December 31, 2003
    Date of Patent: February 7, 2012
    Assignee: University of Maryland, Baltimore
    Inventors: Larry Augsburger, Ngoc Do, Min Michael He, Cheng Der Tony Yu
  • Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
    Publication number: 20110245314
    Abstract: A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a ?2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the ?2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.
    Type: Application
    Filed: April 8, 2011
    Publication date: October 6, 2011
    Inventors: Henry Joseph Horacek, Min Michael He, Moise A. Khayrallah
  • Extended release formulation and method of treating adrenergic dysregulation
    Patent number: 7884122
    Abstract: A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a a2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the a2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: February 8, 2011
    Assignee: Shionogi Pharma, Inc.
    Inventors: Henry Joseph Horacek, Min Michael He, Moise A. Khayrallah
  • Extended Release Formulation and Method of Treating Adrenergic Dysregulation
    Publication number: 20100209510
    Abstract: A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a ?2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the ?2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.
    Type: Application
    Filed: September 16, 2009
    Publication date: August 19, 2010
    Inventors: Henry Joseph Horacek, Min Michael He, Moise A. Khayrallah
  • Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
    Publication number: 20100172991
    Abstract: A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a ?2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours (e.g., no more than once about every 24 hours) to a subject having a steady state plasma concentration of the ?2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.
    Type: Application
    Filed: December 23, 2009
    Publication date: July 8, 2010
    Inventors: Henry Joseph Horacek, Min Michael He, Moise A. Khayrallah
  • EXTENDED RELEASE FORMULATION AND METHOD OF TREATING ADRENERGIC DYSREGULATION
    Publication number: 20100063123
    Abstract: A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a a2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the a2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.
    Type: Application
    Filed: November 10, 2009
    Publication date: March 11, 2010
    Inventors: Henry Joseph Horacek, Min Michael He, Moise A. Khayrallah
  • EXTENDED RELEASE FORMULATION AND METHOD OF TREATING ADRENERGIC DYSREGULATION
    Publication number: 20090087490
    Abstract: A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a ?2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the ?2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.
    Type: Application
    Filed: June 6, 2008
    Publication date: April 2, 2009
    Applicant: Addrenex Pharmaceuticals, Inc.
    Inventors: Henry Joseph Horacek, Min Michael He, Moise A. Khayrallah
  • Novel tablets incorporating isoflavone plant extracts and methods of manufacturing water soluble polymer-based rapidly dissolving tablets and production processes thereof
    Publication number: 20040105903
    Abstract: The invention is directed to novel tablets comprising isoflavone-containing plant extract and water-insoluble polysaccharides, and methods of manufacturing them.
    Type: Application
    Filed: November 14, 2003
    Publication date: June 3, 2004
    Applicants: Johnson & Johnson Consumer Companies, Inc., Indena, S.P.A.
    Inventors: Min Michael He, Fang-Yu Liu, Joseph A. Fix, Martin Link, Maria L. Kang, Ezio Bombardelli
  • Tablets incorporating isoflavone plant extracts and methods of manufacturing them
    Patent number: 6669956
    Abstract: The invention is directed to novel tablets comprising isoflavone-containing plant extract and water-insoluble polysaccharides, and methods of manufacturing them.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: December 30, 2003
    Assignees: Indena S.p.A., Johnson & Johnson Consumer Companies, Inc.
    Inventors: Min Michael He, Fang-Yu Liu, Joseph A. Fix, Martin Link, Maria L. Kang, Ezio Bombardelli
  • Water soluble polymer-based rapidly dissolving tablets and production processes thereof
    Publication number: 20030129226
    Abstract: The invention provides for novel compressed tablets capable of rapidly disintegrating in aqueous solutions, comprising at least one non-saccharide water soluble polymer, which are free of organic solvent residues, and methods of making such pharmaceuticals.
    Type: Application
    Filed: October 9, 2002
    Publication date: July 10, 2003
    Applicant: YAMANOUCHI PHARMA TECHNOLOGIES, INC.
    Inventors: Fang-yu Liu, Min Michael He, Janaki Ram Nyshadham, Kuldeepak Sharma, James Shunnan Chu, Joseph A. Fix
  • Novel tablets incorporating isoflavone plant extracts and methods of manufacturing them
    Publication number: 20020182275
    Abstract: The invention is directed to novel tablets comprising isoflavone-containing plant extract and water-insoluble polysaccharides, and methods of manufacturing them.
    Type: Application
    Filed: May 23, 2002
    Publication date: December 5, 2002
    Applicant: Johnson & Johnson Consumer Companies, Inc.
    Inventors: Min Michael He, Fang-Yu Liu, Joseph A. Fix, Martin Link, Maria L. Kang, Ezio Bombardelli
  • Water soluble polymer-based rapidly dissolving tablets and production processes thereof
    Patent number: 6465009
    Abstract: The invention provides for novel compressed tablets capable of rapidly disintegrating in aqueous solutions, comprising at least one non-saccharide water soluble polymer, which are free of organic solvent residues, and methods of making such pharmaceuticals.
    Type: Grant
    Filed: March 18, 1998
    Date of Patent: October 15, 2002
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Fang-yu Liu, Min Michael He, Janaki Ram Nyshadham, Kuldeepak Sharma, James Shunnan Chu, Joseph A. Fix
  • Tablets incorporating isoflavone plant extracts and methods of manufacturing them
    Patent number: 6413546
    Abstract: The invention is directed to novel tablets comprising isoflavone-containing plant extract and water-insoluble polysaccharides, and methods of manufacturing them.
    Type: Grant
    Filed: March 18, 1999
    Date of Patent: July 2, 2002
    Assignees: Indena, S.p.A., Johnson & Johnson Consumer Companies, Inc.
    Inventors: Min Michael He, Fang-Yu Liu, Joseph A. Fix, Martin Link, Maria L. Kang, Ezio Bombardelli